One month on: medical cannabis is still taboo despite change in law
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.
On 1 November, the UK legalised the use of medical cannabis on prescription, but, just over one month on, medical professionals are still reluctant to prescribe the drug and restrictive guidelines have left families in need disappointed and seeking help elsewhere.
The change in legislation has granted accessibility to cannabis-derived medicines for exceptional cases as seen in the high profile stories of Billy Caldwell and Alfie Dingley, but despite the new rules being a landmark move for UK medicine, experts argue it's not straightforward as not everyone will be granted a licence.
Under the new regulations, only specialist doctors are able to prescribe medical cannabis and those who want to obtain CBD oil for medical purposes have to apply for a licence under a temporary approval panel. Clinicians wanting to prescribe the drug have to prove exceptional clinical circumstances and need to demonstrate that there is no other lawful medicinal product that meets the specific needs of the patient.
Some 250,000 people currently use the treatment method, a number which has doubled in the last year, according to Cannabis Trades Association UK, but due to limited accessibility those in need are turning to alternative CBD oil products available on the free market.
The explosion in demand has led to huge levels of production with many companies doing so without the attention to detail or understanding required to make a product that is destined for UK consumption.
Henry Vincenty, CEO of organic CBD oil producer, Endoca, comments: “Although the change in legislation is something to celebrate, education about CBD products and the plant are still severely lacking.
“Higher demand for CBD means products which have not been standardised or have not undertaken quality testing are coming to market. What many consumers do not know is that hemp and cannabis plants are bioremediators, meaning they absorb all compounds present in the soil they are grown in - including all pesticides and heavy metals. If not quality tested and produced organically, some products can be harmful to our bodies.”
Research has found that CBD extracts can help with conditions including multiple sclerosis and nausea from cancer treatment, but most notably CBD has made huge strides with the treatment of epilepsy. There are currently 600,000 people in the UK living with epilepsy with approximately 1,000 dying from intense seizures every year. The use of CBD medicine can reduce seizures by around 50%, granting a longer and better-quality life for those affected.
Vincenty continues: “Whilst the change in UK legislation is a step in the right direction, changing the law is only half the battle. Currently there are still children and families suffering needlessly due to the denial of access.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance